Novavax, Inc.’s recombinant COVID-19 vaccine candidate NVXCoV2373, given with its Matrix-M adjuvant, elicited robust antibody responses numerically better than those seen in human convalescent sera, and was generally well-tolerated, the first data from its Phase I/II study show.
The results come from the Phase I portion of the trial which evaluated two doses of the vaccine administered at...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
